Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep;316(3):e250949.
doi: 10.1148/radiol.250949.

Emphysema at Baseline Low-Dose CT Lung Cancer Screening Predicts Death from Chronic Obstructive Pulmonary Disease and Cardiovascular Disease Up to 25 Years Later

Collaborators, Affiliations

Emphysema at Baseline Low-Dose CT Lung Cancer Screening Predicts Death from Chronic Obstructive Pulmonary Disease and Cardiovascular Disease Up to 25 Years Later

Jessica González Gutiérrez et al. Radiology. 2025 Sep.

Abstract

Background The prognostic value of baseline visual emphysema scoring at low-dose CT (LDCT) in lung cancer screening cohorts is unknown. Purpose To determine whether a single visual emphysema score at LDCT is predictive of 25-year mortality from all causes, chronic obstructive pulmonary disease (COPD), and cardiovascular disease (CVD). Materials and Methods In this prospective cohort study, asymptomatic adults aged 40-85 years with a history of smoking underwent baseline LDCT screening for lung cancer between June 2000 and December 2008. Follow-up continued until death, loss to follow-up, or December 31, 2024. Emphysema was assessed at baseline LDCT and scored from 0 (none) to 3 (severe) by one of four experienced chest radiologists. Baseline smoking history and comorbidities were self-reported. Causes of death (International Classification of Diseases, 10th Revision) were obtained from the U.S. National Death Index, physicians, and family. Associations between emphysema and mortality were evaluated using adjusted Cox proportional hazards and adjusted Fine-Gray competing risks models. Results Among 9047 participants (4614 female; median age, 65 years [IQR, 61-69 years]; median pack-years of smoking, 43 [IQR, 28-64]), 2637 (29.1%) had emphysema (mild in 1908 [21.1%], moderate in 512 [5.7%], and severe in 217 [2.4%]). Median follow-up was 23.3 years. Emphysema was independently predictive of all-cause mortality (hazard ratio [HR], 1.29; 95% CI: 1.21, 1.38; P < .001), COPD mortality (HR, 3.29; 95% CI: 2.59, 4.18; P < .001), and CVD mortality (HR, 1.14; 95% CI: 1.01, 1.29; P = .04). A dose-response relationship was observed between emphysema severity and both all-cause and COPD mortality, but not CVD mortality. In the adjusted competing risk analysis, emphysema remained associated with COPD mortality (HR, 3.06; 95% CI: 2.40, 3.90; P < .001), but not CVD mortality (HR, 1.04; 95% CI: 0.91, 1.18; P = .59). Conclusion Baseline emphysema at LDCT in a prospective lung cancer screening cohort of asymptomatic adults was predictive of all-cause, COPD, and CVD mortality up to 25 years later. © RSNA, 2025 Supplemental material is available for this article. See also the editorial by Mascalchi and Diciotti in this issue.

PubMed Disclaimer

Conflict of interest statement

Disclosures of conflicts of interest: J.G.G. No relevant relationships. R.Y. No relevant relationships. J.J.Z. Consulting fees from Median Technologies and Heart Lung Technologies, payment of honoraria from Median Technologies for a webinar; stock or stock options in Heart Lung Technologies. S.M.A. No relevant relationships. D.M.L. No relevant relationships. M.W.P. No relevant relationships. D.F.Y. Partial support from the Simons Foundation International; royalties or licenses from General Electric; named inventor on a number of patents and patent applications with General Electric related to the evaluation of chest diseases including measurements of chest nodules and has received financial compensation for the licensing of these patents; on an advisory board for and owns equity in HeartLung; on medical advisory boards for Median Technologies, Carestream, and LungLife AI; and consultant and co-owner of Accumetra. C.I.H. Partial support from the Simons Foundation International, participation on an advisory board for Lunglife AI, named inventor of the patents and pending patents owned by Cornell Research Foundation (since 2009, has divested herself of all royalties and other interests arising from these), president and board member of Early Diagnosis and Treatment Research Foundation (receives no compensation).

References

    1. The definition of emphysema. Report of a National Heart, Lung, and Blood Institute, Division of Lung Diseases workshop . Am Rev Respir Dis 1985. ; 132 ( 1 ): 182 – 185 . - PubMed
    1. Lynch DA , Austin JHM , Hogg JC , et al . CT-Definable Subtypes of Chronic Obstructive Pulmonary Disease: A Statement of the Fleischner Society . Radiology 2015. ; 277 ( 1 ): 192 – 205 . - PMC - PubMed
    1. Bergin C , Müller N , Nichols DM , et al . The diagnosis of emphysema. A computed tomographic-pathologic correlation . Am Rev Respir Dis 1986. ; 133 ( 4 ): 541 – 546 . - PubMed
    1. Zulueta JJ , Wisnivesky JP , Henschke CI , et al . Emphysema scores predict death from COPD and lung cancer . Chest 2012. ; 141 ( 5 ): 1216 – 1223 . - PMC - PubMed
    1. Steiger D , Siddiqi MF , Yip R , Yankelevitz DF , Henschke CI ; I-ELCAP investigators . The importance of low-dose CT screening to identify emphysema in asymptomatic participants with and without a prior diagnosis of COPD . Clin Imaging 2021. ; 78 : 136 – 141 . - PubMed

MeSH terms